{"id":"abcbf02673f4","type":"article","url":"https://hartvaat.nl/2026/05/18/helios-b-post-hoc-vutrisiran-effectief-bij-oost-aziatische-attr-cm-patienten-hr-/","title":"HELIOS-B post-hoc: vutrisiran effectief bij Oost-Aziatische ATTR-CM-patiënten (HR 0,20 voor mortaliteit/CV-events)","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["vrouwen"],"journal":"JACC. Asia","doi":"10.1016/j.jacasi.2026.03.031","source_url":"https://doi.org/10.1016/j.jacasi.2026.03.031","authors":["Jin Endo","Tetsuo Minamino","Jaewon Oh","Nobuhiro Tahara","Kenichi Tsujita","Chisato Izumi","Takahiro Okumura","Kenji Onoue","Hiroaki Kitaoka","Chongshu Chen","Amy Chan-Daniels","Darae Kim"],"significance":6,"published":"2026-06-17","source_date":"2026-05-18","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/","https://hartvaat.nl/kennis/hartfalen/hypertrofische-cardiomyopathie/"],"congress":"","summary_en":"Post-hoc analysis of 32 East Asian participants (Japan and South Korea) from the phase 3 HELIOS-B trial of vutrisiran in transthyretin amyloidosis cardiomyopathy (ATTR-CM), randomised to vutrisiran (n=17) or placebo (n=15). Baseline tafamidis use was lower than in the overall population. Vutrisiran reduced the composite primary endpoint of all-cause mortality and recurrent cardiovascular events (HR 0.20; 95% CI 0.04-0.93). Attenuated declines in 6-minute walk distance and KCCQ-OS scores were observed, and a greater proportion maintained or improved NYHA functional class. NT-proBNP and troponin I increases were smaller with vutrisiran. Similar trends were seen in patients not on baseline tafamidis. Safety matched the overall population. Vutrisiran is thus effective and safe in East Asian ATTR-CM patients.","created":"2026-07-03T10:33:04Z","updated":"2026-07-03T13:31:58Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Post-hoc analyse van 32 Oost-Aziatische deelnemers (Japan en Zuid-Korea) uit de fase 3 HELIOS-B-studie naar vutrisiran bij transthyretine-amyloïdose-cardiomyopathie (ATTR-CM), gerandomiseerd tussen vutrisiran (n=17) en placebo (n=15). Baseline-tafamidisgebruik was lager dan in de gehele populatie. Vutrisiran verlaagde het samengestelde primaire eindpunt van totale sterfte en recidiverende cardiovasculaire events (HR 0,20; 95%-BI 0,04-0,93). Vermindering werd gezien in achteruitgang van 6-minuten-loopafstand en KCCQ-OS-score; vaker bleef NYHA-klasse stabiel of verbeterde. NT-proBNP- en troponine-I-stijgingen waren kleiner met vutrisiran. Vergelijkbare trends bij patiënten zonder baseline-tafamidis. Het veiligheidsprofiel kwam overeen met de hoofdpopulatie. Vutrisiran is dus effectief en veilig bij Oost-Aziatische ATTR-CM-patiënten.","abstract_original":"BACKGROUND: In the phase III Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (HELIOS-B), vutrisiran significantly reduced all-cause mortality and recurrent cardiovascular events and preserved functional capacity and quality of life. However, data in East Asian populations remain limited. OBJECTIVES: The authors aimed to assess the efficacy and safety of vutrisiran in East Asian patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) enrolled in HELIOS-B. METHODS: This post-hoc analysis included 32 patients from Japan and South Korea randomized to vutrisiran (n = 17) or placebo (n = 15). The primary endpoint was a composite of all-cause mortality and recurrent cardiovascular events for up to 36 months. Secondary endpoints were changes from baseline to month 30 in the 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, and New York Heart Association (NYHA) functional class. Exploratory endpoints included changes in N-terminal pro-B-type natriuretic peptide and troponin I. Safety was also evaluated. RESULTS: Baseline characteristics were generally similar to the overall population, although baseline tafamidis use was lower in East Asian patients. Vutrisiran reduced the risk of the composite primary endpoint vs placebo (HR: 0.20; 95% CI: 0.04-0.93). Vutrisiran attenuated declines in 6-minute walk test distance and KCCQ-OS scores, and a greater proportion of patients maintained or improved NYHA functional class. Smaller increases in N-terminal pro-B-type natriuretic peptide and troponin I levels were observed with vutrisiran vs placebo. Similar trends were observed in patients not receiving baseline tafamidis. Safety was consistent with the overall population. CONCLUSIONS: In East Asian patients with ATTR-CM from HELIOS-B, the efficacy and safety of vutrisiran were consistent with the overall population. (NCT04153149)."}